Search
Ethotoin
go.drugbank.com/drugs/DB00754ApprovedThe mechanism of action is probably very similar to that of phenytoin. … Ethotoin is no longer commonly used.
Synonyms: (±)-3-ethyl-5-phenylhydantoin, 3-ethyl-5-phenylhydantoinCategories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersVenlafaxine
go.drugbank.com/drugs/DB00285ApprovedInvestigational[L43030] The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. … for the management of neuropathic pain (although there is only minimal evidence of efficacy for this condition).
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, P-glycoprotein inhibitorsProducts: VENLAVITAE® 75 MG CÁPSULAS DURAS DE LIBERACIÓN PROLONGADA, VENOXOR®75 MGFlorquinitau (18F)
go.drugbank.com/drugs/DB19215Approved[L64052] It binds to aggregated tau protein, which in Alzheimer's disease forms the neurofibrillary tangles (NFTs) that are one of the two components required for a neuropathological diagnosis of the disease … [L64052] Florquinitau F 18, also known as MK-6240, was approved by the FDA on August 14, 2026 for PET of the brain in adults with cognitive impairment who are being evaluated for Alzheimer's disease
Synonyms: 5-isoquinolinamine, 6-(fluoro-18f)-3-(1h-pyrrolo(2,3-c)pyridin-1-yl)-, 6-fluoro-3-(1h-pyrrolo(2,3-c)pyridin-1-yl)isoquinolin-5-amineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesAcenocoumarol
go.drugbank.com/drugs/DB01418ApprovedInvestigationalAcenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase. … [A188739] Hematocrit, hemoglobin, international normalized ratio and liver panel should be monitored. Patients on acenocoumarol are prohibited from giving blood.
Categories: 4-Hydroxycoumarins, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexSynonyms: 4-Hydroxy-3-(1-(4-nitrophenyl)-3-oxobutyl)-2H-1-benzopyran-2-one, 4-Hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-oneMacimorelin
go.drugbank.com/drugs/DB13074ApprovedWhile there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection … Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesIslatravir
go.drugbank.com/drugs/DB15653ApprovedInvestigational[A275492] On April 21, 2026, the FDA approved the first fixed-dose combination containing islatravir (0.25 mg) and the NNRTI doravirine (100 mg), marketed as IDVYNSO, as a complete once-daily regimen for … Islatravir is a first-in-class, highly potent nucleoside reverse transcriptase translocation inhibitor (NRTTI) used in combination therapy for the treatment of HIV-1 infection.
Synonyms: 4'-ethynyl-2-fluoro-2'-deoxyadenosineCategories: Heterocyclic Compounds, 2-RingEdrophonium
go.drugbank.com/drugs/DB01010ApprovedA rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.
Synonyms: 3-hydroxy-N,N-dimethyl-N-ethylanilinium, N-ethyl-3-hydroxy-N,N-dimethylaniliniumCategories: Compounds used in a research, industrial, or household settingEtrasimod
go.drugbank.com/drugs/DB14766ApprovedInvestigational[L48501] The European Commission also approved the marketing of etrasimod on February 19, 2024.[L50998] … Etrasimod is a synthetic next-generation selective Sphingosine 1-phosphate (S1P) receptor modulator that targets the S1P<sub>1,4,5</sub> with no detectable activity on S1P<sub>2</sub> and S1P<sub>3</sub
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-RingHexocyclium
go.drugbank.com/drugs/DB06787ApprovedHexocyclium is a muscarinic acetylcholine receptor antagonist which was presumably used in the treatment of gastric ulcer or diarrhea. … Proton pump inhibitors like [DB00338] and opiate anti-diarrheal agents like [DB00836] have largely replaced the use of anti-muscarinics in the treatment of gastric ulcers and diarrhea due to their more
Categories: Heterocyclic Compounds, 1-RingVedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigational[A261576] Vedolizumab is administered by IV infusion over a period of 30 minutes; after the first dose, it is given again at two and six weeks and then every 8 weeks thereafter. … Vedolizumab is a recombinant humanized IgG1 monoclonal antibody directed against the human lymphocyte α4β7 integrin, a key mediator of gastrointestinal inflammation implicated in diseases like ulcerative
Products: ENTYVIO SC, ENTYVIO® 108 MG SOLUCIÓN INYECTABLE